Shanghai Pharmaceuticals Valuation
| S1R Stock | EUR 1.58 0.01 0.63% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Shanghai Pharmaceuticals has a current Real Value of €1.7 per share. The regular price of the company is €1.58. Our model measures the value of Shanghai Pharmaceuticals from inspecting the company fundamentals such as Operating Margin of 0.04 %, return on equity of 0.1, and Shares Outstanding of 919.07 M as well as reviewing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Shanghai Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Shanghai Pharmaceuticals is based on 3 months time horizon. Increasing Shanghai Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Shanghai stock is determined by what a typical buyer is willing to pay for full or partial control of Shanghai Pharmaceuticals Holding. Since Shanghai Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Shanghai Stock. However, Shanghai Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.58 | Real 1.7 | Hype 1.58 |
The real value of Shanghai Stock, also known as its intrinsic value, is the underlying worth of Shanghai Pharmaceuticals Company, which is reflected in its stock price. It is based on Shanghai Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Shanghai Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Shanghai Pharmaceuticals Holding helps investors to forecast how Shanghai stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Shanghai Pharmaceuticals more accurately as focusing exclusively on Shanghai Pharmaceuticals' fundamentals will not take into account other important factors: Shanghai Pharmaceuticals Total Value Analysis
Shanghai Pharmaceuticals Holding is at this time estimated to have takeover price of 8.94 B with market capitalization of 9.17 B, debt of 7.16 B, and cash on hands of 23.68 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Shanghai Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.94 B | 9.17 B | 7.16 B | 23.68 B |
Shanghai Pharmaceuticals Investor Information
About 22.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.67. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Shanghai Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 2.42. The entity last dividend was issued on the 20th of July 2022. Based on the key indicators related to Shanghai Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Shanghai Pharmaceuticals Holding is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Shanghai Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Shanghai Pharmaceuticals has an asset utilization ratio of 132.05 percent. This implies that the Company is making €1.32 for each dollar of assets. An increasing asset utilization means that Shanghai Pharmaceuticals Holding is more efficient with each dollar of assets it utilizes for everyday operations.Shanghai Pharmaceuticals Ownership Allocation
Shanghai Pharmaceuticals shows a total of 919.07 Million outstanding shares. Shanghai Pharmaceuticals maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Shanghai Pharmaceuticals Profitability Analysis
The company reported the revenue of 215.82 B. Net Income was 5.09 B with profit before overhead, payroll, taxes, and interest of 28.41 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Shanghai Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Shanghai Pharmaceuticals and how it compares across the competition.
About Shanghai Pharmaceuticals Valuation
The stock valuation mechanism determines Shanghai Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Shanghai Pharmaceuticals. We calculate exposure to Shanghai Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Shanghai Pharmaceuticals's related companies.Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the Peoples Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical Co., Ltd. SHANGHAI PHARM operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 46609 people.
8 Steps to conduct Shanghai Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Shanghai Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Shanghai Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Shanghai Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Shanghai Pharmaceuticals' revenue streams: Identify Shanghai Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Shanghai Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Shanghai Pharmaceuticals' growth potential: Evaluate Shanghai Pharmaceuticals' management, business model, and growth potential.
- Determine Shanghai Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Shanghai Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Shanghai Stock analysis
When running Shanghai Pharmaceuticals' price analysis, check to measure Shanghai Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Pharmaceuticals is operating at the current time. Most of Shanghai Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shanghai Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shanghai Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |